HeinzLenzMD

PubMed

• 109 citations
  ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
  David J. Park, Wu Zhang, Jan Stoehlmacher, Denice D. Tsao-Wei, Susan Groshen
  Clinical Advances in Hematology & Oncology. 2003-03-01
• 288 citations
  A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer
  Stoehlmacher J, David J. Park, Wu Zhang, D. Y. Yang, Susan Groshen
  British Journal of Cancer. 2004-07-13
• 21 citations
  Mucinous Adenocarcinomas with Intra-Abdominal Dissemination: A Review of Current Therapy
  Thomas Winder, Heinz-Josef Lenz
  The Oncologist. 2010-08-01

Journal Articles

• Primary Tumor Sidedness as Prognostic and Predictive Biomarker in Metastatic Colorectal Cancer: Further Validation of a Potentially Practice-Changing Variable  
  Lenz H-J, JAMA Oncol, 1/10/2016
• Response  
  Cremolini C, Loupakis F, Lenz HJ, J Natl Cancer Inst, 1/1/2015
• S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma  
  El-Khoueiry AB, Rankin C, Siegel AB, Iqbal S, Gong IY, Micetich KC, Kayaleh OR, Lenz HJ, Blanke CD, Br J Cancer, 1/1/2014
• Intratumoral expression profiling of genes involved inangiogenesis in colorectal ancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK222584 (vat...  
  Wilson PM, Yang D, Azuma M, Shi MM, Danenberg KD, Lebwohl D, Sherrod A, Ladner RD, Zhang W, Danenberg PV, Trarbach T, Folprecht G, Meinhardt G, Lenz HJ, Pharmacogenomics J, 1/1/2012
• Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase...  
  Zwicker Jl, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, Mantha S, Kessler CM, Eneman J, Raghavan V, Lenz HJ, Bullock A, Buchbinder E, Neuberg D, Furie B, BR J Heamatol, 1/1/2012
• Using The Colon Cancer Multigene Recurrence Score to Determine Risk: Prognostic Milestone or a Step in the Right Direction?  
  Wilson PM, Bohanes P, Lenz HJ, Curr Colorectal Cancr, 1/1/2010
• Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating gemonics into biomarker discovery  
  Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H, Proutski V, S..., Oncologist, 1/1/2010
• Thymidylate synthase gene variation: predictive and prognostic markers  
  Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W, Lenz H-J, Mol Cancer Ther, 1/1/2009
• Regulation human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplation-induced DNA damage  
  Wilson PM, Fazzone W, LaBonte M, Lenz H-J, Ladner RD, Nucleic Acids Research, 1/1/2009
• Polymorphisms in Interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer  
  Lurje G, Hendifar AE, Schultheis AM, Pohl A, Husain H, Yang D, Manegold P, Ning Y, Zhang W, Lenz H-J, Pharmacogenetics & Genomics, 1/1/2009
• Histone deacetylase in hibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells  
  Fazzone W, Wilson PM, Labonte MJ, Lenz HJ, Ladner RD, International Journal of Cancer, 1/1/2009
• Messenger RNA expression of COX-2 and angiogenic factors in primary colorectal cancer and corresponding liver metastasis  
  Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S, Lenz H-J, Danenberg K, Danenberg PV, International Journal of Oncology, 1/1/2009
• Phase III trial of irinotecan/ciplatin compared with etoposide/cisplatin in extensive stage small-cell lung cancer: clinical and pharmacogenomic results from Southwest...  
  Lara PN Jr., Natale R, Crowley J, Lenz H-J, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR, J Clin Oncol, 1/1/2009
• Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer  
  Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz H-J, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef ML, Ganda..., J Clin Oncol, 1/1/2009
• The 8q24 cancer risk variant rs6983267 demonstrates long-range interaction with MYC in colorectal cancer  
  Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, Yao K, Kehoe SM, Lenz H-J, Haiman CA, Yan C, Henderson BE,..., Nature Genetics, 1/1/2009
• Gender Disparties in metastatic colorectal cancer survival  
  Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, Ning Y, Zhang W, Lenz HJ, Clinical Cancer Research, 1/1/2009
• EGFR signaling and drug discovery  
  Lurje G, Lenz HJ, Oncologist, 1/1/2009
• Pharmacogenomics and -genetics in colorectal cancer  
  Pohl A, Lurje G, Manegold PC, Lenz HJ, Advanced Drug Delivery Reviews, 1/1/2009
• Chemotherapy with Targeted Agents for Treatment of Metastatic Colorectal Cancer  
  Kohne C-H, Lenz H-J, The Oncologist, 1/1/2009
• DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines  
  LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz H-J, Ladner RD, BMC Medical Genomics, 1/1/2009
• Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Marg...  
  Garcia A, Hirte H, Fleming G, Yang D, Tsao-Wei D, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz H-J, Oza A, J Clin Onc, 1/1/2008
• Predictive and prognostic markers in colorectal cancer  
  Wilson PM, Ladner RD, Lenz H-J, GastroIntestinal Ca Res, 1/1/2008
• Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: A study by the National Cancer ...  
  Gibbons J, Egorin M, Ramanathan R, Fu P, Mulkerin D, Shibabta S, Takimoto C, Mani S, LoRusso P, Grem J, Pavlick A, Lenz H-J, Flick S, Reynolds S, Lagattuta T, Parise R..., J Clin Onc, 1/1/2008
• The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study  
  Davies AM, Ruel C, Lara PN, Lau DH, Gumerlock PH, Bold R, Shibata S, Lenz HJ, Schenkein DP, Gandara DR, J Thoracic Onc, 1/1/2008
• Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer  
  Lurje G, Zhang W, Yang D, Groshen S, Hendifar A, Husain H, Nagashima F, Chang FM, Fazzone W, Ladner R, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz H-J, Pharmacogenetics & Genomics, 1/1/2008
• Join now to see all

Books/Book Chapters

• Modern Management of Benign and Malignant Pancreatic Disease 
  Chapter: Pancreatic Cancer: Medical Management (Novel Chemotherapeutics). 
  Page 189 - 211Paez D, Labonte MJ, Lenz HJEditors: Jacques Van Dam, MD, PhD.W.B. Sauders Company A Division of Elsevier Inc. Gastroenterology Clinics of North America2012
• Prediction Markers in Clinical Development 
  Chapter: Biomarkers in Oncology 
  Lenz HJHumana Press2011
• Adenocarcinoma of the Esophagogastric Junction 
  Chapter: Molecular Response Prediction in Multimodality Treatment for Adenocarcinoma of the Esophagus and Esophagogastric Junction. 
  Page 179 - 186Lurge G, Lenz H-JEditors: Schneider PM.Springer-Verlag, Berlin-Heidelberg2010
• Metastasis of Colorectal Cancer 
  Chapter: Molecular Prognostic Markers In Colon Cancer 
  Page 321 - 342Winder T, Lenz H-JEditors: Beauchemin N, Huot J.Springer Science and Business Media B.V., The Netherlands2010
• Principles and Practice of Surgical Oncology: A Multidisciplinary Approach to Difficult Problems 
  Chapter: Cancer of the Pancreas: Adjuvant and Neoadjuvant Therapy 
  Page 694 - 704Park D, Lenz H-JEditors: Silberman H, Silberman AW.Lippincott, Williams & Wilkins, Philadelphia, PA2009
• Esophageal Cancer: Principles and Practice 
  Chapter: Rationale for Tailored Treatment 
  Page 219 - 228Lurje G, Lenz H-JDemos Medical Publishing, New York2009
• Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response 
  Chapter: Role of Thymidylate Synthase Gene Variations in Colorectal Cancer Patients 
  Page 151 - 172Lurje G, Lenz H-JEditors: Innocenti F.Humana Press, Totowa, NJ2008
• DeVita, Hellman, and Rosenberg's Cancer Principles and Practice of Oncology 
  Chapter: Pharmacogenomics 
  Page 402 - 406El-Khoueiry A, Lenz H-JEdition 8th,2008
• Bioinformatics in Cancer and Cancer Therapy 
  Chapter: Personalized Medicine in the Clinical Management of Colorectal Cancer. 
  Page 155 - 172El-Khoueiry A, Lenz H-JEditors: Gordon GJ.Humana Press, Totowa, NJ2008
• Colorectal Cancer: Evidence Based Chemotherapy Strategies 
  Chapter: Second line strategies in the treatment of patients with metastatic colorectal cancer. 
  Page 119 - 130El-Khoueiry A, Lenz HJEditors: Saltz LB.Humana Press, New York2007
• Atlas of Gastrointestinal Cancers 
  Chapter: Molecular biology and pharmacogenomics in GI cancers. 
  Page 195 - 210El-Khoueiry A, Lenz HJ2006
• Praxis der Viszeralchirurgie 2 
  Chapter: Moglichkeiten der Response Prediction. 
  Valbohmer D, Lenz HJEditors: Siewert, Rothmund, Schumpelick.2006
• New Trends in Cancer for the 21st Century - Advances in Experimental Medicine and Biology 
  Chapter: Pharmacogenomics and Colorectal Cancer. 
  Page 211 - 231Lenz, H-JEditors: Lopez-Guerrero JA, Blombart-Bosch A, Felipo V.Springer, New York2006
• Challenges in Colorectal Cancer 
  Chapter: Future directions in the treatment of colorectal cancer. 
  Page 251 - 270El-Khoueiry A, Lenz HJEditors: Scholefield J, Maughan T, Abcarian H, Grothey A.Blackwell Publishing, Oxford, EnglandEdition 2nd,2006
• The Oncogenomics Handbook 
  Chapter: Proteasome Inhibition in Its Clinical Application in Solid Tumors. 
  Page 493 - 508Park DJ, Lenz H-JEditors: Larochelle WJ, Shimkets RA.Human Press,, Totowa, NJ2006
• Viszeralchirurgie 
  Chapter: Potential Response Prediction in the Neoadjuvant and Adjuvant Therapy of Esophageal and Gastric Cancer. 
  Page 249 - 254Vallbohmer D, Lenz H-J2005
• Handbook of Anticancer Pharmacokinetics and Pharmacodynamics 
  Chapter: Polymorphisms in genes of drug targets and metabolism, and DNA repair. 
  Page 231 - 243Stoehlmacher J, Iqbal S, Lenz H-JEditors: William Figg, Howard McLeod.Human Press Inc., Totowa, NJEdition 1st,2004
• Der Onkologe 
  Chapter: Pharmakogenetik in Kolorektalen Karzinomen. 
  Schneider S, Stoehlmacher J, Lenz H-J2003
• Surgical Oncology: Multidisciplinary Approach to Difficult Problems 
  Chapter: Principles of adjuvant and neoadjuvant therapy: applications in gastric and pancreatic cancer. 
  Page 574 - 584Iqbal S, Lenz H-JEditors: Silberman H, Silberman AW.Oxford University Press, New York, NYEdition 1st,2002
• PCR Methods and Applications 
  Chapter: Rapid Quantitative PCR for Determination of Relative Gene Expressions in Tissue Specimens. 
  Lenz HJ, Hill C, Danenberg K, Leichman L, Priest DG, Danenber PVCold Spring Harbor Laboratory Press1995
• Reverse Transcriptase PCR 
  Chapter: Quantitative measurement of relative gene expression in human tumors. 
  Lenz H-J, Danenberg KD, Danenberg PVSimon and Schuster1994
• Cancer Gene Therapy 
  Chapter: Bestimmung der Androstendionspiegel im Serum von Kindern mit Ullrich-Turner 
  Lenz, H-J1989
• Join now to see all

Abstracts/Posters

• Differences in molecular profiles of males and females with colorectal cancer (CRC).
  Barzi A, Salem ME, Xiu J, Korn WM, Marshall J, Shields AF, Lenz H-J, J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• Association of genetic variations within the PD-L2 immune checkpoint gene with outcome in stage II and III colon cancer.
  Berger MD, Zlobec I, Yang D, Cao S, Sunakawa Y, Matsusaka S, Koelzer VH, Inderbitzin D, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Soni S, Puccini A, Tokun..., J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• Initial therapy with FOLFOXIRI plus bevacizumab (bev) for RAS mutant metastatic colorectal cancer (mCRC) and gene mutations in circulating tumor DNA (ctDNA) as a predi...
  Sunakawa Y, Satake H, Usher JL, Jaimes YS, Miyamoto Y, Nakamura M, Nakayama H, Sugano N, Takagane A, Gotoh M, Watanabe T, Ishigure K, Tanaka C, Takeuchi M, Fujii M, Da..., J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• Association of RAS mutations with race in metastatic colorectal cancer: CALGB/SWOG 80405 (ALLIANCE).
  Sehdev A, Niedzwiecki D, Venook AP, Lenz H-J, Innocenti F, Mahoney MR, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg R, Mayer RJ, Schilsky RL, Bertagnolli MM, B..., J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• Polymorphism in cancer-associated fibroblasts (CAFs) related genes and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) enrolled in two independe...
  Puccini A, Berger MD, Tokunaga R, Naseem M, Battaglin F, Cao S, Millstein J, Soni S, McSkane M, Zhang W, Loupakis F, Stintzing S, Heinemann V, Falcone A, Lenz H-J, J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• Genetic variants in methylation and demethylation pathways to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FO...
  Puccini A, Loupakis F, Stintzing S, Berger MD, Tokunaga R, Naseem M, Battaglin F, Cao S, Millstein J, Soni S, McSkane M, Zhang W, Heinemann V, Falcone A, Lenz H-J, J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• The impact of Tfh cell/ B cell pathway-related genetic variants in metastatic colorectal cancer patients with bevacizumab-based chemotherapy.
  Tokunaga R, Cao S, Zhang W, Puccini A, Berger MD, Naseem M, Battaglin F, Soni S, McSkane M, Stintzing S, Loupakis F, Heinemann V, Falcone A, Millstein J, Lenz H-J, J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• Polymorphisms in beta-defensin pathways and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI-bevacizumab in two randomized phase III tri...
  Naseem M, Berger MD, Puccini A, Tokunaga R, Battaglin F, Barzi A, Soni S, McSkane M, Cao S, Millstein J, Zhang W, Loupakis F, Stintzing S, Heinemann V, Falcone A, Lenz..., J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes to predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevaciz...
  Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Murgioni S, Lonardi S, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Loupakis F, Falcone A, ..., J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• Assessment of microsatellite instability (MSI) in cell free DNA (cfDNA) of colorectal cancers (CRC) patients (pts).
  Barzi A, Campan M, Petterson J, Du L, Long T, Dubeau L, Lenz H-J, Ward P, J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• Matrix metalloproteinase-related gene polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal cancer.
  Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Bergamo F, Zagonel V, Rossini D, Borelli B, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Yamaguchi T, Lo..., J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer...
  Loupakis F, Hurwitz HI, Saltz L, Arnold D, Grothey A, Nguyen QL, Osborne S, Yau L, Talbot J, Srock S, Lenz H-J, J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-Beta, in patients with heavily pretreated CRC: Preliminary results from a phase I trial.
  Kopetz S, Spira AI, Wertheim M, Kim E, Tan BR, Lenz H-J, Nikolinakos P, Rich P, Smith DA, Helwig C, Dussault I, Ojalvo L, Gulley JL, J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• Molecular characterization of intestinal (IS) and diffuse subtypes (DS) of gastric adenocarcinomas.
  Salem ME, Xiu J, Puccini A, Philip PA, Goldberg RM, Hwang JJ, Kc B, Korn WM, hields AF, Lenz H-J, John Marshall J, J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• A first-in-human phase I study of sEphB4-HSA (sEphB4) with expansion in hepatocellular (HCC) and cholangiocarcinoma (CCA).
  Thomas JS, Lenz H-J, Iqbal S, Tsao-Wei DD, Barzi A, Duddalwar V, Cole S, Rehman R, Menendez X, Krasnoperov V, Liu R, Feng Q, Gill PS, El-Khoueiry AB, J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Fir...
  Andre T, Lonardi S, Wong M, Lenz H-J, Gelsomino F, Aglietta M, Morse M, Van Cutsem E, McDermott RS, Hill AG, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine..., J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)-...
  Bekaii-Saab TS, Ou F-S, Anderson DM, Ahn DH, Boland PM, Ciombor KK, Jacobs NL, Desnoyers RJ, Cleary JM, Meyers JP, Chiorean EG, Pedersen K, Barzi A, Sloan J, McCune JS..., J Clin Oncol, 2018 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/18/2018
• Nintedanib (N) plus best supportive care (BSC) versus placebo (P) plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard ther...
  Lenz HJ, Yoshino T, Argiles G, Iveson T, Sastre J, Harrison M, Lim HJ, Tebbutt NC, Peeters M, Satoh T, Dittrich C, Sassi M, Loembe A-B, Van Cutsem E, 2017 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/19/2017
• Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to stand...
  Lenz HJ, Tabernero J, Yoshino T, Lonardi S, Falcone A, Limon Miron ML, Saunders MP, Sobrero AF, Suk Park Y, Monteagudo RF, Sang Hong Y, Tomasek J, Taniguchi H, Ciardie..., 2017 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/19/2017
• Comparative effectiveness of initiating colorectal cancer (CRC) screening (Scr) at age 45.
  Barzi A, Siegel R, Fedewa SA, Lenz HJ, Quinn DI, Jemal A, Sadeghi S, 2017 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/19/2017
• Molecular characterization of early vs. late onset gastroesophageal cancers.
  Qureshi S, Xiu J, Sarraf Yazdy M, Shields AF, Agop P, Marshall J, Lenz HJ, Salem ME, 2017 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/19/2017
• Effect of polymorphisms of genes encoding regulatory proteins in the coagulation cascade on outcome for mCRC patients treated with FOLFIRI and bevacizumab: Data from F...
  Berger MD, Stintzing S, Yang D, Suenaga M, Miyamoto Y, Cao S, Soni S, Gopez R, Hanna HL, Zhang W, Heinemann V, Lenz HJ, 2017 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/19/2017
• Molecular characterization of squamous cell carcinoma of the anal canal (SCCA).
  Weinberg BA, Lenz HJ, Arguello D, El-Deiry WS, Xiu J, Gatalica Z, Liu Z, Chen S, El Ghazaly H, Hwang JJ, Philip PA, Shields AF, Marshall J, Salem ME, 2017 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/19/2017
• Randomized trial of irinotecan and cetuximab with or without vemurafenib in�BRAF-mutant metastatic colorectal cancer (SWOG 1406).
  Kopetz S, McDonough SL, Van Karlyle Morris VK, Lenz HJ, Magliocco AM, Atreya CE, Diaz LA, Allegra CJ, Wang SE, Hanyoung Lieu C, Eckhardt GS, Semrad TJ, Kaberle K, Guth..., 2017 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/19/2017
• Effect of JAK2 SNP rs2274472 on outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.
  Berger MD, Stintzing S, Heinemann V, Yang D, Cao S, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Gopez R, Hanna DL, Zhang W, Lenz HJ, 2017 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/19/2017
• Join now to see all

Lectures

• Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update. 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
• A phase Ib/II study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second-line treatment of metastatic colorectal cancer (mCRC) in patients w... 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
• Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colore... 
  2019 ASCO Annual Meeting - 6/1/2019
• Personalised Treatment in mCRC. Personlising therapy in mCRC. 
  Galway, Ireland; Limerick, Ireland; Dublin, Ireland - 1/28/2017
• Improving Outcome in mCRC inhibiting Multiple Pathways. 
  Mexico City, Mexico - 1/24/2017
• Personalized Medicine in Metastatic Colorectal Cancer. An Update and Comprehensive Review. 
  Los Angeles, CA - 1/21/2017
• Medical Oncologist. 
  San Francisco, CA - 1/19/2017
• Putting it all together: Future Directions, Trials and Sequencing Therapies. 
  Los Angeles, CA - 1/18/2017
• How can we optimize treatment to maximize efficacy? Differentiation of targeted theray in RAS wt mCRC. 
  Bangkok, Thailand - 1/12/2017
• Current and Future targets in CRC. 
  Vienna, Austria - 1/10/2017
• Highlights of the Day: GI Colorectal. 
  Chicago, IL - 1/6/2017
• Management of Microsatellite Instability High Colorectal Cancer: Early and Advanced Stage. 
  Chicago, IL - 1/5/2017
• New Venues in Neuroendocrine Tumors Research and Management. 
  Tel Aviv, Isreal - 1/2/2017
• Molecular Landscape of Colon Cancer; Beyond Ras and Braf. 
  National University of Singapore, Singapore - 1/31/2016
• Regorafenib in Gastrointestinal Stromal Tumor GIST. 
  Cairo, Egypt - 1/30/2016
• Controversy: is colorectal cancer a matter of bad luck? 
  Barcelona, Spain - 1/29/2016
• Molecular Ladscape in Colorectal Cancer. 
  Carmel, CA - 1/29/2016
• Prolonging Survival in Metastatic Colorectal Cancer. 
  Pasadena, CA - 1/27/2016
• Personalising Treatment in mCRC. Getting it Right: Practical Approaches for Patients. 
  London - 1/22/2016
• Role of targented thearpy in the management of mCRC - Bet sequencing option. 
  Abu Dhabi, UAE - 1/21/2016
• Molecular profiling in colorectal cancer: Which genes do you commonly test for, and why? How MOA (mechanism of actions) of agents will impact combination approaches to... 
  San Francisco, CA - 1/21/2016
• Role of targeted therapy in the management of mCRC. 
  Qatar; Oman - 1/20/2016
• Molecular landscape of mCRC look into the future. 
  China - 1/20/2016
• Management of mCRC patients, best sequencing option and Role of immuno therapy in GI cancer. 
  Kuwait, UAE - 1/19/2016
• Advice for strategic alignment for the therapy of colorectal cancer. 
  Basel, Switzerland - 1/17/2016
• Join now to see all

Other

• Metastatic Colorectal Cancer: Results of The Mavericc Study. 
  Lenz HJ, The ASCO Post
  1/26/2016
• Nintedanib Externale expert filming session with the subject colorectal cancer. 
  Lenz HJ, 2016 Gastrointestinal Cancers Symposium (Boehringer Ingelheim International gmBh)
  1/23/2016
• Module 1: Selection and Sequencing of Therapy for Patients with Newly Diagnosed Metastatic Colorectal Cancer (mCRC). 
  Lenz HJ, REAL-LIFE DECISIONS, Clinical Investigators Provide Their Perspectives on Actual Patients with Metas
  San Francisco, CA - 1/21/2016
• Molecular Landscape in mCRC. 
  Lenz H-J, Pfizer Metastatic Colorectal Cancer Webinar
  Tainan, Taiwan - 1/17/2016
• Gastrointestinal Cancer Update 2015 
  Lenz HJ, An Enduring Audio, Print, Podcast, Web and Mobile Interview Series for Medical Oncologists and Other
  Los Angeles, CA - 1/24/2015
• Treatment of Metastatic Colorectal Cancer: Case Study Reports Outlining Second-line and Later-live Options. 
  Lenz HJ, OncLive Peer Exchange
  San Francisco, CA - 1/17/2014
• Virtual Interactive Education Module for Multikinase Inhibition in mCRC and GIST. 
  Lenz HJ, ECCO/ESMO Bayer Stivarga
  Amsterdam, Netherlands - 1/30/2013
• Genomics of Metastasis 
  Lenz HJ, Vital Options 1:1 Interview
  Chicago, IL - 1/3/2013
• Buying Time: Funding Cutting Edge Cancer Research and Patient Needs. 
  Lenz HJ, Inaugural Dinner for The Danny Butler Memorial Fund, Inc.
  Manhattan, NY - 1/12/2011
• Charla con el Dr. Heinz-Josef Lenz, "Hay una revolucion molecular en cuanto al cancer de colon" 
  Lenz HJ, La Capital New Paper, XX Congreso internacional Federacion Lation Americana De Sociedades De Cancero
  Mar Del Plata, Argentina - 1/10/2011
• Managing treatment side effects for colorectal cancer. 
  Lenz HJ, Vital Options International The Group Room Cancer Talk Radio Show
  Los Angeles, CA - 1/22/2009
• Erbitux 
  Lenz HJ, TV clip that went to air in Channel 10 News
  Melbourne, Australia - 1/17/2009
• Optimizing Treatment Regimens for Colorectal Cancer: Hightlights from the 2009 ASCO GI Cancer Annual Meeting (CBCE). 
  Lenz HJ, Oncology Uplugged Interview
  San Francisco, CA - 1/17/2009
• Pancreatic Cancer 
  Lenz HJ, ABC News
  Los Angeles, CA - 1/5/2008
• Molecular Markers. 
  Manegold P, Lenz HJ, New Treatment Strategies for Metastatic Colorectal Cancer
  1/1/2008
• Significance on Kras Mutation Update (CBCE). 
  Lenz HJ, XM Satellite Radio at Annual ASCO Meeting
  1/1/2008
• Treatment of colorectal cancer since the introduction of irinotecan. 
  Lenz HJ, A Supplement to Community Oncology
  1/1/2007
• Pharmacogenomics and Molecular Biology in Gastrointestinal Cancers. 
  El-Khoueiry A, Lenz H-J, Atlas in GI Cancers
  1/1/2006
• Colorectal Cancer Update. 
  Lenz HJ, Group Room/Vital Options Radio Talk Show
  Encino, CA - 1/23/2005
• Cancer Talk- Colorectal Cancer. 
  Lenz HJ, Vital Options (Recorded via telephone)
  1/22/2005
• Cancer Care: Medical Update on Pancreatic Cancer. 
  Lenz H-J, Telephone Educational Workshop
  1/18/2005
• Strike Out Cancer and New Discoveries. 
  Lenz HJ, Wellness Community
  Redondo Beach, CA - 1/10/2005
• Conversations with Oncology Research Leaders. Bridging the Gap between Research and Patient Care. 
  Lenz HJ, Colorectal Cancer Update- Think Tank
  Chicago, IL - 1/1/2005
• Prognostic and predictive factors in systemic therapy, ongoing translational studies. 
  Lenz HJ, Colorectal Cancer Update- Research Leader Think Tank (Organized by Dr. Neil Love)
  Chicago, IL - 1/30/2004
• Genetic profiling to predict response to 5-FU/platinum combinations - Colorectal Cancer Update. 
  Lenz HJ, Conversations with Oncology Research Leaders: Bridging the Gap Between Research and Patient Care, Au
  Palm Beach, FL - 1/1/2004
• Join now to see all